Israeli - Kiingereza - Ministry of Health

teva israel ltd - sertraline as hydrochloride - film coated tablets - sertraline as hydrochloride 50 mg - sertraline - sertraline - for the treatment of symptoms of depression in patients with or without a history of mania. following satisfactory response, continuation with sertaline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

Israeli - Kiingereza - Ministry of Health

teva israel ltd - sertraline as hydrochloride - film coated tablets - sertraline as hydrochloride 100 mg - sertraline - sertraline - for the treatment of symptoms of depression in patients with or without a history of mania. following satisfactory response, continuation with sertaline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sertraline hydrochloride, quantity: 111.8 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; methylcellulose; magnesium stearate; hypromellose; hyprolose; titanium dioxide; iron oxide yellow; colloidal anhydrous silica; macrogol 8000 - sertraline is indicated in adults for the treatment of 1) major depression; 2) premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sertraline hydrochloride, quantity: 55.9 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; methylcellulose; magnesium stearate; hypromellose; hyprolose; titanium dioxide; indigo carmine; colloidal anhydrous silica; macrogol 8000 - sertraline is indicated in adults for the treatment of 1) major depression; 2) premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sertraline hydrochloride 111.9mg equivalent to 100 mg sertraline;   - film coated tablet - 100 mg - active: sertraline hydrochloride 111.9mg equivalent to 100 mg sertraline   excipient: calcium hydrogen phosphate hyprolose hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 sodium starch glycolate titanium dioxide - sertraline actavis is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sertraline hydrochloride 55.95mg equivalent to 50 mg sertraline;   - film coated tablet - 50 mg - active: sertraline hydrochloride 55.95mg equivalent to 50 mg sertraline   excipient: calcium hydrogen phosphate hyprolose hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 sodium starch glycolate titanium dioxide - sertraline actavis is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

Marekani - Kiingereza - NLM (National Library of Medicine)

remedyrepack inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline hydrochloride tablets are indicated for the treatment of the following [see clinical studies (14)] : - major depressive disorder (mdd) - obsessive-compulsive disorder (ocd) - panic disorder (pd) - posttraumatic stress disorder (ptsd) - social anxiety disorder (sad) - premenstrual dysphoric disorder (pmdd) sertraline hydrochloride tablets are contraindicated in patients: - taking, or within 14 days of stopping, maois, (including the maois linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)] . - taking pimozide [see drug interactions (7.1)] . - with known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [see adverse reactions (6.1, 6.2)]. risk summary overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in compar

Marekani - Kiingereza - NLM (National Library of Medicine)

greenstone llc - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline hydrochloride is indicated for the treatment of the following [see clinical studies (14)] : sertraline hydrochloride is contraindicated in patients: in addition to the contraindications for all sertraline hydrochloride formulations listed above, sertraline hydrochloride oral solution is contraindicated in patients: risk summary overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in comparator populations. some studies have reported increases for specific major birth defects; however, these study results are inconclusive [see data] . there are clinical considerations regarding neonates exposed to ssris and snris, including sertraline hydrochloride, during the third trimester of pregnancy [see clinical considerations]. although no teratogenicity was observed in animal reproduction studies, delayed fetal ossification was observed when se